Yunnan Biovalley Pharmaceutical Co (BJSE:920266) Research & Development: ¥1.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BJSE:920266 Yunnan Biovalley Pharmaceutical Co Ltd BJSE:920266
74 GF Score
Price ¥7.57
GF Value ¥7.81
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Yunnan Biovalley Pharmaceutical Co Research & Development?

Yunnan Biovalley Pharmaceutical Co BJSE:920266 74 Research & Development is ¥1.0 Mil as of Jun. 2026. GuruFocus rates BJSE:920266 with a GF Score™ of 74/100 and a GF Value™ of ¥7.81 (Fairly Valued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Yunnan Biovalley Pharmaceutical Co's Research & Development for the three months ended in Jun. 2026 was ¥1.1 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was ¥1.0 Mil.

Yunnan Biovalley Pharmaceutical Co  (BJSE:920266) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Yunnan Biovalley Pharmaceutical Co Research & Development Related Terms

Yunnan Biovalley Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Yunnan Biovalley Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yunnan Biovalley Pharmaceutical Co Research & Development Chart

Yunnan Biovalley Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.57 15.37 20.13 13.19 5.59

Yunnan Biovalley Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.57 1.85 -2.94 1.02 1.08
BJSE:920266
74GF Score
Yunnan Biovalley Pharmaceutical Co Ltd BJSE:920266
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yunnan Biovalley Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥1.0 Mil mean?
Yunnan Biovalley Pharmaceutical Co (BJSE:920266) has a Research & Development of ¥1.0 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Yunnan Biovalley Pharmaceutical Co and its competitors.
Is Yunnan Biovalley Pharmaceutical Co's Research & Development too high?
Yunnan Biovalley Pharmaceutical Co's current Research & Development is ¥1.0 Mil. Overall, Yunnan Biovalley Pharmaceutical Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Yunnan Biovalley Pharmaceutical Co's Research & Development compare to ZTS?
Yunnan Biovalley Pharmaceutical Co's Research & Development of ¥1.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Yunnan Biovalley Pharmaceutical Co and its competitors. Yunnan Biovalley Pharmaceutical Co's current Research & Development is ¥1.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yunnan Biovalley Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Yunnan Biovalley Pharmaceutical Co (BJSE:920266) is currently considered Fairly Valued. The stock's GF Value™ is ¥7.81, compared to a current price of ¥7.57 — trading 3.1% below its estimated fair value. The current Research & Development is ¥1.0 Mil. Yunnan Biovalley Pharmaceutical Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Yunnan Biovalley Pharmaceutical Co (BJSE:920266), the current Research & Development is ¥1.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Yunnan Biovalley Pharmaceutical Co (BJSE:920266) Overvalued in 2026?

Based on GuruFocus' analysis, Yunnan Biovalley Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥7.57 is trading 3.1% below its estimated GF Value™ of ¥7.81. GuruFocus considers Yunnan Biovalley Pharmaceutical Co to be Fairly Valued.

Key valuation signals for BJSE:920266:

  • Research & Development: ¥1.0 Mil
  • GF Value™: ¥7.81 vs. price of ¥7.57 (3.1% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the BJSE:920266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Yunnan Biovalley Pharmaceutical Co Business Description

Address No. 999 Biological Valley Street, Majinpu New District, High-tech Zone, Yunnan Province, Kunming City, CHN, 650500
Yunnan Biovalley Pharmaceutical Co Ltd engages in research and development, production, and marketing of pharmaceuticals and health care based on herbal medicines. The products on the market include breviscapine injection, breviscapine Shengmai capsules, breviscapine tablets, breviscapine dripping pills, Erigeron Capsules, Erigeron Soft Capsules.
74GF Score

Get the complete analysis for BJSE:920266

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.57
Price
¥7.81
GF Value